[Tumor markers in gynecologic malignancies].
Human chorionic gonadotropin (hCG) is widely used as a tumor specific index substance for the trophoblastic disease. The radioimmunoassay (RIA) of the C-terminal peptide of hCG-beta subunit can detect hCG up to the level of 0.5 IU/day in urine or 0.5mIU/ml in serum without cross-reactivity with luteinizing hormone. Therefore, this RIA would be used as a hCG-specific assay method in order to ensure the disease is in complete remission and to detect early recurrence. Alpha-fetoprotein and lactic dehydrogenase can be used as a sensitive tumor marker for embryonal carcinoma and dysgerminoma respectively. Carcinoembryonic antigen may serve as a valuable aid in monitoring the response to the therapy of the patient with ovarian or cervical carcinoma, but may not be useful for early detection of these diseases.
D002272:Carcinoembryonic Antigen / Q000032:analysis; D006063:Chorionic Gonadotropin / Q000032:analysis; D005260:Female; D005833:Genital Neoplasms, Female / Q000032:analysis*; D006801:Humans; D007770:L-Lactate Dehydrogenase / Q000097:blood; D010051:Ovarian Neoplasms / Q000032:analysis; D014594:Uterine Neoplasms / Q000032:analysis; D000509:alpha-Fetoproteins / Q000032:analysis
D002272:Carcinoembryonic Antigen; D006063:Chorionic Gonadotropin; D000509:alpha-Fetoproteins; D007770:L-Lactate Dehydrogenase